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Asthma is one ofthe most common diseases
in both adults and children in the United
States. A major risk factor for the develop-
ment of asthma is atopy. Atopy generally
refers to the development of immune
responses to foreign antigens that are charac-
terized by the production ofantigen-specific
IgE. Development of atopic responses has
been linked to several genes and gene prod-
ucts. Thus, atopic diseases represent a com-
plex gene-environment interaction in which
environmental antigens interact with the
immune system, producing atopic (IgE)
responses. Furthermore, other genes are likely
important for full expression of asthma in
individuals. In addition to interaction
between antigens and the host immune sys-
tem, other environmental and lifestyle factors
may impact immune responsiveness such that
IgE-type immune responses are favored over
nonallergic responses.
The processes that mediate immune
responses to antigens are reviewed in this
paper, along with examples of how such
processes are altered by genetic defects and
environmental and lifestyle influences that
may support the development of atopic
responses. Ofspecial interest are environ-
mental and lifestyle factors that may act
before conception, during gestation, or dur-
ing early childhood such that an atopic or
asthmatic phenotype is found within a given
individual. Identification of environmental
factors present during these critical windows
ofexposure may allow for intervention from
both a personal and a public health perspec-
tive. Avoidance of these agents during
important periods in immune development
could result in decreased expression of
atopic/asthmatic phenotypes in genetically
susceptible individuals.
Asthma and Atopy
Asthma is a complex multifactorial disease
that is characterized by reversible airway
obstruction, airway hyperresponsiveness, and
eosinophilic airway inflammation (1). Atopy
is the most significant risk factor for asthma
development, with approximately 85% of
children who develop asthma and 40-50% of
adults with new-onset asthma having an aller-
gic response to aeroallergens (1-4). Several
studies reveal a link between IgE and asthma
(2,4-8). Even in nonatopic asthma, the pres-
ence ofeosinophilic airwayinflammation sug-
gests that similar atopic-like immune
processes are important in the development
ofthis disease (1,9).
However, atopy alone does not account
for asthma: many persons are atopic but not
asthmatic. Given the multiple processes
involved in asthma pathogenesis, it seems
likely that several genes play a role in asthma
development. One example is airway hyper-
responsiveness, an important defining feature
ofasthma. A polymorphism ofthe gene that
codes for the 32 receptor is associated with
airway hyperresponsiveness and may mediate
this phenomenon in asthma (10). The loca-
tion ofthis gene is of interest-it is located
near a cluster ofgenes on chromosome 5q,
which plays a key role in mediating atopic
inflammation. Although it has been thought
that atopic inflammation causes airway
hyperresponsiveness, the clustering ofthese
genes provides an alternate explanation for
the link between atopy and airway hyper-
reponsiveness in asthma.
Environmental influences are also an
important determinant in the development
of an atopic or asthmatic phenotype.
Persons prone for development ofatopy may
only develop such responses if living in
environments that induce expression of
proatopy genes. Prime examples ofsuch envi-
ronments are those rich in airborne (house
dust mite and pollen) and orally encountered
antigens (11). Likewise, with decreased expo-
sure to such environmental factors, there is
often a decrease in the severity ofatopic dis-
ease in affected individuals (3,12). The effects
ofair pollutants, lifestyle factors, and urban-
ization on the development of atopy and
asthma are more controversial.
A logical target for examination of the
effect ofenvironment and lifestyle on develop-
ment ofasthma is the effect ofenvironmental
influences on the immune response to anti-
gens, with emphasis on development ofatopy.
Antigen Presentation
Development of immune responses to
specific antigens is a complex process, and it
has been reviewed elsewhere (13,14). Initially,
antigens are taken up by a number of cells
that can act as antigen-presenting cells,
which, as their name implies, process antigens
and then present them to either CD8+ or
CD4+ T lymphocytes. These lymphocytes
then direct specific immune responses against
processed specific antigens. CD8+ lympho-
cytes direct responses against derived antigens
produced within host cells, whereas CD4+
lymphocytes direct responses against antigens
encountered outside ofthe host cell (13,14).
Antigen presentation to CD8+ cytotoxic
cells requires major histocompatibility com-
plex (MHC) class I molecule expression on
the surface ofthe cell that is presenting the
antigen. All body cells express MHC class I
molecules and the antigens typically pre-
sented to CD8+ lymphocytes are neoantigens
produced within the host cell itself. These
antigens usually include tumor antigens or
viral proteins generated during the viral life
cycle in which viral DNA or RNA uses the
protein-generating capability ofthe host cell.
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Antigenic proteins are processed in the host
cell cytoplasm by proteosomes, which results
in the production ofderivative antigenic pep-
tides. These peptides are then transported to
the endoplasmic reticulum in the Golgi appa-
ratus. MHC proteins and 12 macroglobulin
are produced in the Golgi apparatus and the
antigenic peptide is complexed with these
molecules and transported to the host cell
membrane. This complex interacts with the
CD8+ lymphocyte via the T-cell receptor, the
CD8 molecule, and the CD3 receptor that
are clustered on the surface on the CD8 cell.
These activated CD8+ cells then attack the
host cell bearing the antigenic peptides,
destroying that cell and, when effective, the
source ofthe antigenicpeptides (13,14).
Immune responses directed against
proteins produced outside ofhost cells are
directed by CD4+ T lymphocytes. These anti-
gens, which usually derive from bacteria,
extracellular viral partides, uni- or multicellu-
lar parasites, or molecules produced by plants
or animals, are processed by specialized or
professional antigen-presenting cells (APCs).
A number ofcells can act as APCs, including
dendritic cells in the skin, alveolar macro-
phages, B lymphocytes, and venular endothe-
lial cells. The unique antigen presentation
function ofthese cells is mediated by expres-
sion ofMHC class II molecules (13,14).
APCs take up antigen viaphagocytosis and
digest these extracellularly derived molecules in
a lysosome or endosome. Independently,
MHC II molecules are generated in the Golgi
apparatus. Vesides containing MHC II mole-
cules then fuse with the endosomes containing
digested foreign antigens and the antigen is
bound to the MHC II molecule. Thiscomplex
is then transported to the surface ofthe APC
and interacts with clustered receptors on the
surface oftheCD4+ Tlymphocyte.
These cell molecules include the CD4+
receptor, the T-cell receptor, and the CD3
molecule. After the MHC II-antigen com-
plex interacts with the surface molecules of
the CD4+ T cell, the T cell is activated. The
resulting immune response ultimately results
in production ofimmunoglobulins directed
against specific antigens (or antibodies) as
well as secretion of a number ofcytokines
that promote growth and differentiation of
effector cells in bone marrow and other tis-
sues which complete the immune response
directed against the specific antigen (13,14).
A number ofinherited immune defects
demonstrate how essential these processes are
in directing immune responses (15). Defects
in expression ofCD3 and the T-cell receptor
by lymphocytes are a cause ofone variant of
severe combined immune deficiency (SCID).
Defects in tyrosine kinase activity, such as a
lack of ZAP-70, also result in SCID.
Lymphocytes are also susceptible to build-up
ofproducts ofpurine metabolism. Ifthey are
lacking in enzymes that allow metabolism of
purines to nontoxic products, lymphocyte
cytotoxicity occurs, resulting in other variants
of SCID. These syndromes exemplify how
alterations inAPC/T-cell interaction orT-cell
physiology alter immune responses. Although
these cited alterations are due to genetic
defects, environmental agents that target
these processes could also impact the ultimate
nature of the immune response to inhaled
antigens.
AtopicT Helper (Th)-2
Versus Nonatopic Thi
Immune Responses
There is no formal or standardized definition
for atopy. Persons are thought to be atopic if
they have one ofa number oftypical allergic
clinical syndromes, induding atopic dermati-
tis, food allergy, allergic rhinitis, and at least
certain forms ofasthma, such as that which
typically exists in early childhood. Atopic
responses are often seen in response to a num-
ber ofallergens (such as animal, plant, or fun-
gal antigens), which may be encountered by
oral or inhalant routes or venoms from sting-
ing insects. One difficulty in defining atopy is
that manypersons maydevelop several allergic
diseases or they may only manifest with one
disease. Likewise, persons who are otherwise
thought to be nonatopic maymount an atopic
response to an isolated antigen, such as a
venom from a stinging insect, or a protective
eosinophilic response to multicellular para-
sites. Nonetheless, a key feature in any func-
tional definition ofatopy is the development
ofIgEantibodies directed againstspecific anti-
gens, which is often associated with eosinophil
and mast cell activity (13,14).
Conversely, CD4+-mediated responses
that result in IgG production and neutrophilic
inflammation are thought to be nonatopic.
Nonatopic responses are typically elicited by
bacteria and viruses that are encountered as
the result ofthe infection oftissues. Atopic
and nonatopic immune responses occur in
persons who have an atopic disease. However,
it is interesting to note that many immune
deficiency diseases with blunted nonallergic
responses are associated with phenotypic fea-
tures ofatopy, such as eczema and increased
IgEproduction (13,14).
CD4+ lymphocytes direct B cells to
produce immunoglobulin directed against
specific antigens. B cells require antigen-bind-
ing and T-cell help to proceedwith the initial
formation of IgM. Activation of CD40 by
CD40 ligand [a member ofthe tumor necro-
sis factor (TNF)-a family] is necessary for
this response. This activation is expressed on
T lymphocytes. IgM is the initial immuno-
globulin response to any antigen by B cells,
and increases in circulating IgM correlate
with initial exposure to a particular antigen.
After producing IgM, B lymphocytes eventu-
ally mature into plasma cells that secrete IgA,
IgG, or IgE. The process ofswitching from
IgM to production of one of the final
immunoglobulin classes also requires activa-
tion ofCD40 (13,14).
IgA is produced in the mucosa and is
secreted by mucosal cells onto the lumen of
the airway and gastrointestinal tracts. IgA is
also secreted into breast milk, where it is pas-
sively consumed by infants. IgA exists as a
dimer and binds to antigens, keeping them
from adhering to mucosal surfaces and gain-
ing entry into the body proper. IgG exists in
the bloodstream as monomers; four subclasses
ofIgG have been identified. IgGI and IgG3
are thought to bind protein antigens and
IgG2 and IgG4 recognize polysaccharides.
Receptors for IgG (FcYRI, -II, and -III) are
found on anumber ofeffector cells, including
polymorphonuclear neutrophils (PMNs).
IgG binds to bacteria and can also activate
complement (via domains on the CH3 region
ofthe molecule). IgG can confer protection
against foreign antigens by facilitating phago-
cytosis ofantigens by PMNs via FcyRs or by
activation of complement, which directly
causes foreign cell lysis or allows for interac-
tion ofthe foreign antigen with phagocytes
via complement receptors. Interestingly,
IgG4 is associated with IgE and the true
function ofIgG4 is not dearlyunderstood.
IgE is primarily produced in local tissues
(such as the gut or airway) and, after being
secreted by IgE-producing plasma cells, binds
to cells that bear either high-affinity (FcERI)
or low-affinity (FcERII or CD23) receptors.
FcERI receptors are expressed by mast cells
and basophils and cross-linking of IgE on
these cells leads to the release ofhistamine
and production of a number ofcytokines.
CD23-bearing cells include eosinophils and
platelets. In general, IgA impedes antigen
binding to mucosal surfaces, IgG facilitates
neutralization or phagocytosis offoreign anti-
gens, and IgE induces histamine release and
other phenomena associated with atopy or
response toparasites (13,14).
Cytokine Mediation ofThi
and Th2 Responses by
CD4+ Lymphocytes
There is a difference in cytokine secretion
profiles of CD4+ T cells recovered from
atopic and nonatopic subjects (16,17). These
cytokines mediate specific responses in
immune cells and other tissues that result in
the Thl and Th2 characteristics outlined in
"Atopic T Helper (Th)-2 Versus Nonatopic
Thl Immune Responses" (11). A summary
ofthese cytokine actions follows [reviewed
by Blumenthal (3) and Borish and
Rosenwasser (16)].
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Cytokines associated with Thl responses
include interleukin (IL)-2, interferon-y, and
IL-12. IL-2 is secreted by Thl cells and stim-
ulates clonal expansion of antigen-specific
T cells, CD8 cell maturation, and is a switch
factor for B lymphocytes, inducing them to
mature from IgM-secreting cells to IgGI-
secreting cells. IL-2 is thought ofas a Thl
cytokine, and is essential for all immune
function defects in the IL-2 receptor in lym-
phocytes. IL-2 receptor defects also account
for one ofthe most common forms ofSCID.
Interferon-y induces expression ofFc7Rs,
MHC class I, and MHC class II molecules on
the surface ofmacrophages (facilitating their
actions as antigen-presenting cells), promotes
B cells to switch from secretion of IgM to
IgG2, inhibits B cell switch to IgE secretion,
and induces other T cells to express a Thl
rather than Th2 cytokine phenotype. IL-12 is
primarily secreted by macrophages (an
antigen-presenting cell) and acts on T lym-
phocytes to induce secretion ofa Thl rather
than Th2 cytokine profile.
Cytokines associated with Th2 responses
includeIL-4, IL-5, IL-10, and IL-13 (Table 1).
IL-4 acts on B lymphocytes to induce the
switch from IgM secretion to IgE and IgG4
secretion and also contributes to the expres-
sion ofVCAM-1 on endothelial cells in post-
capillary venules. VCAM-1 is a ligand for
VLA-4, a molecule expressed on eosinophil
membranes. Interaction ofthese molecules is
essential for migration ofeosinophils from the
bloodstream to end-organ tissues. IL-5 pro-
motes eosinophil maturation and survival.
IL-10 acts on macrophages to inhibit expres-
sion ofMHC class II molecules and inhibits
Thl responses by blunting production of
interferon-y. This cytokine also promotes T
cells to exhibit aTh2 phenotypebyenhancing
Table 1. Summary of some keycytokines in atopy.
Cytokine Description
GM-CSF An importantgrowth factor for neutrophils,
eosinophils, and macrophages
IL-1 An important T-lymphocyte activator
IL-3 Ahematopoeitic cell growth factor impor-
tant in mast cell and eosinophil growth
[l-4 Mediates immunoglobulin class switching
of B lymphocytes from IgM to IgE;
contributes tothe expression ofVCAM-1,
which allows foreosinophil adhesion
to endothelial cells
IL-5 An importantgrowth factorforeosinophils
[l-8 A potent neutrophil chemoattractant, also
primes eosinophil responses
IL-1D Acts as an anti-inflammatory cytokine;
blunts expression of MHC class 11
molecules on antigen-presenting cells;
blunts secretion of interferon-yby
T lymphocytes
IL-13 Mediates immunoglobulin class switching
of B lymphocytes from IgM to IgE; shares
the action ofIL-4. IL-13 is homologous with
IL-4 and, like IL-4, induces B cell switching
from IgM to IgE.
Many other cytokines promote both Thl
and Th2 responses, including IL-1, IL-3,
IL-8, granulocyte macrophage colony-form-
ing unit (GM-CSF), and TNF-a. IL-1 is
important in general T-cell activation. IL-3 is
an essential growth factor for hematopoeitic
cells, and is essential for mast cell and
eosinophil proliferation. IL-8 is primarily
known as a chemotactic and priming agent
for PMNs, but also has actions on basophils
and eosinophils. GM-CSF is an important
growth factor for neutrophils, eosinophils,
and macrophages. TNF-a has a broad spec-
trum of action, including upregulation of
MHC class I and II molecules and activation
ofvirtually every cell in the immune system.
Ofinterest are general observations exam-
ining the Thl versus Th2 response in
humans (15). All healthy humans, whether
thought to be atopic or not, have a robust
Thl response. Defects in Thl responsiveness
are associated with significant morbidities
linked to decreased immune function
(increased infection and increased incidence
of tumors). Conversely, the majority of
humans do not manifest significant signs of
Th2 immune activation (atopic diseases) and
an apparent lack ofTh2 responses is not rou-
tinely linked to poor health. Many congenital
immunodeficiency states, including several
varieties ofSCID, hyper IgE syndrome, and
Wiskott-Aldrich syndrome, are typified by
diminished Thl and exaggerated Th2
responses. Likewise, exaggeration of atopic
characteristics has been reported in some
acquired immunodeficiency virus patients.
There appears to be a relationship between
decreased Thl function and increased Th2
function. Uncovering the basis for Thl and
Th2 balance may uncover potential targets
for study ofthe effect ofenvironmental expo-
sures on the development ofatopic diseases.
Genes Associated with Atopy
and Asthma
Approximately 10% of the U.S. population
has an atopic disorder (with reports of as high
as 30% having at least one positive skin test
response). An estimated 5-7% of the U.S.
population has asthma. A common feature of
atopic disease is that it develops in susceptible
individuals who experience exposure to sig-
nificant environmental or lifestyle-related
stimuli. Susceptibility for development of
atopic disease appears to have familial associa-
tions and genetic components.
Evidence for a genetic component for
asthma is found in studies ofdisease pheno-
types on twin pairs (3,18,19). There is sig-
nificantly greater concordance among
monozygotic (MZ) twins than dizygotic
(DZ) twins with regard to asthma. MZ twins
exhibited a 19.8% concordance for asthma
versus 4.8% in DZ twins in one study. A sec-
ond study involving 2,902 twin pairs
revealed 30 versus 12% concordance in MZ
versus DZ twins [reviewed by Blumenthal
(3) and Edfors-Dubs (19)]. With atopy
rather than asthma as an end point, 50-60%
concordance has been reported in twin pairs.
These studies indicate that there is a genetic
component for asthma and/or atopy.
However, it is clear that not all atopic per-
sons have the same diseases. Even monozy-
gotic twins, who have identical genomes, do
not have 100% concordance with regard to
the development of asthma or atopic dis-
eases. The failure to observe 100% concor-
dance (or even levels approaching 100%)
strongly suggests that environmental as well
as genetic factors influence atopic or asthma
phenotype expression.
The technique ofmapping genes that code
for mediators important in asthma and atopy
(or at least phenotypes or disease characteris-
tics important in asthma or atopy) has been
used to explore the genetic basis ofasthma
and atopy (the candidate gene approach).
Such studies carried out in a number oflabo-
ratories suggest that chromosome 5q31-33
may be important in asthma and atopy, with
genes for IL-3, IL-4, IL-5, IL-13, and GM-
CSF clustered on the 5qlocus (3,20-22). This
technique also indicates that the P subunit of
the high affinity IgE receptor is located on
chromosome 11 q. All-in-all, candidate gene
studies have suggested linkages ofpotentially
important genes with regions 5q (12 AR and
those listed above), 6p (HLA-DR), 1 lq, 12q
(interferon-Y), 13q, and 14q (TCR).
Positional cloning techniques (3) allow
for examination ofthe genome for loci associ-
ations with phenotypic features ofasthmatic
and atopic subjects without a priori knowl-
edge ofthe inflammatory or immune func-
tion of any subsequently identified DNA
sequences. Such studies suggest linkages of
asthma or atopy with regions 2q, 5p, 1 Ip,
17p, 19q, and 21q (18-22).
Development of Atopy
and Asthma
Prenatal and Preconcepiional Influences
(Parental Influences and Exposures)
Aside from having a genetic predisposition
for atopy, no specific preconceptional influ-
ences that are strongly linked to development
of atopy have been identified in humans. Th2
responses can clearly occur in fetal life, as
demonstrated by antigen-specific IgE and the
presence ofallergen-responsive lymphocyte
and mononuclear cells in cord blood
(5,7,11,232). Furthermore, infants can
have positive skin tests to food allergens,
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presumably due to maternal ingestion offood
allergens. However, attempts at decreasing
maternal exposure to food allergens have not
been shown to decrease fetal levels ofIgE or
the likelihood ofthe child having atopic dis-
ease (11). Nonetheless, several studies have
shown that maternal factors outweigh pater-
nal factors in the development ofatopy or
asthma in children (11,28). These observa-
tions support the hypothesis that maternal
influences, whether genetic, transplacental, or
environmental, may play a role in the devel-
opment ofatopyorasthma.
Recent studies have focused on immune
function of neonates as it relates to atopy
development. Several studies showed that
mononuclear cells recovered from cord blood
have robust proliferative responses to stimu-
lation with allergens [including house dust
mite antigen, rye grass pollen extract, FeldI
(cat allergen), ovalbumin, and ,-lactoglobu-
lin]. Similarly, stimulated cord blood
mononuclear cells secreted Th2 cytokines,
including IL-4, IL-5, IL-9, IL-10 and IL-13.
It is noteworthy that the Th2-type cord
blood mononuclear cell (CBMC) responses
occur both in infants who were thought to
be at low risk for development of atopy
(based on family history) as well as those
thought to be at higher risk for atopy
(11,24,29-35). Interferon-y also appears to
be important in the development ofatopy at
a young age (30,31,36-38). Interferon-y is
associated with Thl responses, antagonizes
the action ofIL-4, and blunts production of
IL-4 (16). Studies in many laboratories
demonstrate that CBMCs or peripheral
blood mononuclear cells from neonates have
diminished ability to produce interferon--y
compared to cells from normal adults after
stimulation with mitogens. This blunting
generally resolves by 5 years ofage. However,
there appears to be a trend in which inter-
feron-~y responses in cells obtained from chil-
dren who develop atopic disease are even
more blunted than those from nonatopic
children. Some have argued that production
of adult levels of interferon-y by mono-
nuclear cells occurs later in atopic children
than in nonatopic children. Thus, blunting
ofThl responses may be important in main-
taining Th2 responses.
These results, and others, have led to the
argument that a Th2 phenotype is relatively
universal in all neonates and that subsequent
postnatal development ofatopy may be due
to the failure ofThl responses to adequately
develop. This notion is supported by animal
observations that dendritic cell function is
dampened in neonatal rodents. This prevents
robust Thl responses from occurring during
fetal life. It has been speculated that dampen-
ing Thl responses is important for fetal sur-
vival and that all infants are predisposed for
atopy until Thi stresses (and response to
those stresses) occur (24,25,31,3!).
Postnatal Influences andthe
DevelopmentofAtopyand
Atopyin Children
Early exposure to allergens in susceptible
individuals has been postulated as an impor-
tant factor in development ofan atopic phe-
notype (eczema, rhinitis, or asthma) during
childhood. Correlations between early expo-
sure to seasonal airborne allergens and devel-
opment ofatopic responses to those allergens
have been reported. Specifically, seasonal
allergens prevalent during the first month of
life seem to predict eventual development of
atopic airway disease related to that allergen
in later childhood. Similar arguments have
been made regarding house dust mite expo-
sure, with children living in environments
with increased levels ofmite allergen in col-
lected house dust during the first year oflife
being more likely to develop asthma. Studies
that examined efforts to reduce the incidence
ofatopic airwaydisease by decreasing allergen
exposure during the first year oflife are in the
very early stages. One such study reported
that the combination ofdecreased airway and
oral allergen exposure seems to decrease inci-
dence ofatopic diseases at 2 and 4 years of
age (5,11,31).
Perhaps better understood is the relation-
ship between food allergen exposure and the
development ofatopic responses [reviewed by
the Early Treatment of the Atopic Child
study group (5), Bjorksten et al. (11), and
Platts-Mills et al. (37)]. Positive allergy skin
tests have been reported within the first 3
months oflife in nearly30% ofchildren born
to atopic parents. The disease state most com-
monly associated with food allergy in infants
is eczema, and 80-90% of infants with
eczema will develop a positive skin test to air-
borne allergens. It has been argued that both
maternal and neonatal exposure to food aller-
gens contributes to the development ofspe-
cific allergen responses. A milk and egg
allergy is perhaps the most common ofthe
foodallergy states in infants (5,11).
Infants who are exclusively breast-fed
appear to have decreased risk for the develop-
ment offood allergy than infants who are not
breast-fed or who are have other food expo-
sures. It has also been suggested that food
allergens that may be secreted into breast milk
may pose a risk for sensitization in those
exposed infants. Although decreased foreign
food exposure is one mechanism by which
breast-feeding ofinfants may be protective,
the presence ofmaternal IgA in breast milk
may also be important. Although data can be
cited on either side ofthe breast-feeding argu-
ment regarding its role in protection against
food allergies, the weight ofevidence indicates
that food allergen avoidance in at-risk infants
is protective against the development of
atopy (11).
In addition to allergen exposure, maternal
tobacco smoking has also been linked to
increased rates ofwheezing and asthma in
exposed children, increased bronchial reac-
tivity, and increased total and antigen-
specific IgE (11,39-41). Exposure to
environmental tobacco smoke (ETS) may
enhance atopy by a number ofmechanisms.
These include increased airway mucosal per-
meability or direct effect on immune func-
tion. The link between ETS and asthma
appears clear with regard to exacerbation of
preexisting disease. Although there is still
debate on the effect ofETS in the develop-
ment ofasthma or atopy, the preponderance
ofthe evidence supports the hypothesis that
ETS enhances atopy development in suscep-
tible individuals.
Environmental Influences in
the Development ofAtopy
and Asthma
I have outlined "normal" factors that may
influence the development ofasthma and
atopy in fetal life and in early and later child-
hood. These factors primarily dealtwith aller-
gen exposure, maternal dietary exposure, and
patterns ofimmune expression in fetal and
early life. I now expand on the initial review
and examine a number ofpotential lifestyle
and environmental influences that have been
proposed as modulating factors in the devel-
opment of atopy. These include living in
urban versus rural settings, dietary factors,
exercise patterns, having experienced infec-
tions, or the use ofantibiotics (which might
influence deviation ofthe immune system
away from Th2 responses and toward Thl
responses).
Additionally, there are some data examin-
ing the role ofspecific environmental influ-
ences (including ETS, diesel exhaust,
endotoxin exposure, and criteria air pollu-
tants) having an effect on developing certain
patterns ofimmune expression. I reviewwhat
is known or commonly hypothesized about
the role ofthese influences on the develop-
ment ofatopy and asthma and highlight the
known influence ofspecific pollutants on
immune responses.
Lifestyle Influences onthe
DevelopmentofAtopy
A number ofepidemiological studies have
pointed to the potential role oflifestyle as a
factor that modulates the expression ofatopy
in susceptible individuals [reviewed by Platts-
Mills et al. (327]. One ofthe most intriguing
examples ofthe effect oflifestyle is the exami-
nation ofthe prevalence ofasthma and atopy
in children from eastern andwestern Germany
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at times after the political reunification ofthat
state. Shortly after reunification in 1990,
studies ofthe prevalence ofatopy and asthma
in children from East and West Germany
revealed that children from the east, albeit
more likely to be diagnosed with bronchitis,
were less likely to have atopy, had fewer posi-
tive skin tests, and were less likely to have
asthma than their western counterparts (42).
Although it was unclear which lifestyle fac-
tors were influencing atopy development,
there were some candidate influences.
Children in the east were more likely to be
placed in day care than those in the west.
Also, potential differences in diet, especially
fat intake, were suggested as possible influ-
ences. In the early 1990s, particulate pollu-
tion was higher in the east, whereas private
automobile use and ozone exposure were
more common in thewest. Allergen exposure
was not thought to be substantially different
in the east than in thewest.
It is now a few years later, and rates of
atopy in eastern Germany have increased and
are approaching those found in western
Germany. This has been associated with the
development ofa more westernized lifestyle
in the east, including decreased use ofcoal in
industry, increased automobile use, and
increased availability ofhigh-fat foods.
Decreased exercise and changes in architec-
tural style have also been associated with the
development ofatopyand asthma. A compar-
ison ofheating styles in rural versus urban
western Germany shows decreased asthma
and atopy in the rural setting, in which
wood- and coal-burning furnaces are used to
heat homes. Itwas thought that bedroom and
indoor temperatures were less in these homes
than in urban homes, which might contribute
to decreased expression ofatopy. Dampness
and water damage have also been associated
with increased expression ofallergic disease.
Similar observations have been made
between other previously Eastern Bloc and
western countries, as well as comparisons of
asthma in rural versus urban Africa, Europe,
and the Pacific (New Zealand andAustralia).
This effect of more recent westernization of
lifestyle in these locations mirrors the devel-
opment ofasthma in previously westernized
countries. Likewise, the problem ofasthma in
inner-city minority populations suggests a
role for urbanization in the expression of
atopy (37).
All in all, it seems quite likely that urban-
ization is a key feature in the development of
asthma and atopy. This likely represents
alterations in the environment, which allow
for the expression of important genes that
result in an atopic phenotype. Delineation of
the specific features of urban lifestyle that
allow the atopic phenotype to be expressed
is incomplete.
Infections andAntibiotics: Effecton
Thi versusTh2 CytokineExpression
There is evidence to suggest that fetal immune
function is primarily ofthe Th2 type (23-25,
30,31,33,34,37,43). It has been further sug-
gested that environmental stresses which sup-
press Thl responses ofthe infant may allow
for the persistence ofTh2 immune function,
thus increasing the potential for development
ofatopic diseases such as asthma (31,37,44).
Amongthe most frequently reported immuno-
logical features manifesting in children with
atopic diseases is decreased ability ofcirculat-
ing mononuclear cells to produce interferon-y
after in vitro stimulation with either mitogens
or specific allergens (24,30,36,31,45).
Interferon-yplays a key role in expression ofa
Thl phenotype and antagonizes the action of
IL-4, which allows for the development ofIgE.
Against this backdrop, the role ofinterven-
tional modifiers ofThl responsiveness (vac-
cines, infections, and antibiotics) on atopy will
be reviewed.
Perhaps one ofthe most interesting and
controversial observations on the role ofThl
stimuli on Th2 expression is found when
examiningtheeffectofthe antituberculosis vac-
cine Bacillus Calmette-Guerin (BCG) on the
development ofatopy. Japanese schoolchildren,
who routinelyundergo BCG vaccination, hada
significant inverse relationship between delayed
hypersensitivity to Mycobacterium tuberculosis
and incidence ofasthma and elevation ofIgE
(46). As with many studies ofenvironmental
influences on atopic disease, there are con-
founding data. Studies in Britain fail to show a
relationship between response to BCG vaccina-
tion and atopy (46). Furthermore, whether the
observations by Shirakawa et al. (45) result
from theeffectofthevaccine itselfortheinnate
abilityofthatchild to respond to thatvaccine is
open to debate (46). However, experiments in
mice, which demonstrate that immunization
with BCG blunts development ofallergen-spe-
cific IgE and eosinophilic responses to allergen
after allergen challenge, support the idea that
BCG vaccine is a potent Thl stimulus (47).
Taken together, these observations support the
notion that BCG stimulates increased Thl
function and is associated with decreased Th2
immune responsiveness.
It has also been argued that decreased
incidence of infection and frequent use of
antibiotics may also be contributing to the
development ofatopy. The hypothesis is that
by decreasing exposure to Thl stimuli (either
byactive infection or by alteration ofbacterial
colonization, which may stimulate Thl
immune responses), the Th2 immune respon-
siveness expressed by the fetus has a better
chance ofbeing maintained, thus allowing for
expression of the immune phenotype. The
use of antibiotics in the early years of life
correlates with the subsequent development
ofatopy. Similarly, in societies in which anti-
biotic use is decreased and natural infections
are more frequent, atopyoccurs less frequently.
However, despite these data, it seems unlikely
that children at very high risk for asthma
(inner-city African Americans) have increased
exposure to antibiotics compared to more
affluentpopulations at lesserrisk(31,32).
In addition to antigen-specific immune
responses, it has been suggested that accessory
molecules expressed by bacteria (classic Thl
stimuli) may contribute to immune matura-
tion such that Thl responses are emphasized
(31,48). Lipopolysaccharide (LPS) is a mole-
cule expressed on all gram-negative bacteria
that interacts with antigen-presenting cells
and other immune effector cells via the
CD14 receptor. Treatment ofAPCs with
LPS results in secretion ofIL-12, which in
turn blunts Th2 responses and stimulates
interferon-ysecretion. It has been argued that
mucosal colonization with bacteria, including
LPS-bearing organisms, allows for nonspecific
deviation toward the Thl phenotype.
Recently, it was found that the gene for
CD14 colocalizes with genes for IL-3, IL-4,
and GM-CSF on the chromosome region
5q31.1. Furthermore, a specific polymor-
phism has been identified (a C-to-T transi-
tion at base pair -159) in which those
children homozygous for the T allele have
significantly higher levels ofsoluble CD14
than do heterozygotes or those who are
homozygous for the C allele (48). In turn,
serum levels ofCD14 (which could mediate
LPS interaction withAPCs) have a significant
positive correlation with interferon-y and a
negative correlation with IL-4 (48). This
observation supports the hypothesis that an
imbalance between Thl and Th2 influences
the development ofatopic disease.
SpedficPollutants andTheirEffects
onTh2 Inflammation
A number of ambient air pollutants are
thought to contribute to the exacerbation of
asthma. Indeed, criteria pollutants such as
NO2 and O3 have been associated with
asthma exacerbation in epidemiological
studies and, in challenge and animal studies,
can enhance immediate and late-phase
responses to inhaled allergens in already sensi-
tized individuals (49-51). However, with
perhaps some animal data to the contrary,
these pollutants do not appear to play a sig-
nificant role in the actual development ofthe
Th2 phenotype. In contrast, diesel exhaust
particles (DEPs) shift the immune phenotype
toward a Th2 pattern (51).
DEPs. Numerous animal (murine) and in
vitro studies have demonstrated that DEPs
enhance allergen-induced immune responses,
including increasing IgE production and
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enhancing cytokines involved in eosinophilic
or allergic inflammation, especially IL-4, IL-5,
and GM-CSF, as well as airway hyperrespon-
siveness (51-56). DEPs induce B-lymphocyte
immunoglobulin isotype switching to IgE
(57,58). Polyaromatic hydrocarbon residues
on DEPs may be responsible for this effect on
allergic inflammation (56).
Diaz-Sanchez et al. (57) used nasal
challenge studies in humans and reported
that challenge ofvolunteers (four atopic and
seven nonatopic) to DEP increased nasal IgE
production 4 days after DEP challenge with-
out anyeffect on IgG, IgA, or IgM. They also
noted shifts in the ratio ofthe five isoforms of
IgE with the challenge. This effect was very
dose specific; only a 0.3-mg dose of DEP
caused this result.
Diaz-Sanchez et al. (57) also found that
DEP challenge of the nasal mucosa causes
increased cytokine production by cells
recovered in lavage fluid. Subjects under-
went lavage pre- and postchallenge with 0.3
mg DEP. Cells recovered in the prechal-
lenge lavage had detectable mRNA levels for
interferon-y, IL-2, and IL-13, whereas those
recovered postchallenge were associated
with detectable levels of IL-2, IL-4, IL-5,
IL-6, IL-10, IL-13, and interferon-y in
recovered cells. IL-4 protein was also mea-
sured in postchallenge lavage [reviewed by
Peden (50)]. Although it is unclear which
type of cells were present in lavage fluid
before or after challenge, it was not thought
to be due to increased lymphocyte number.
When coupled with challenge with a spe-
cific allergen (ragweed), DEP yielded an
enhanced ragweed-specific IgE and IgG
response to ragweed allergen compared to
ragweed alone. This effect included
increased expression ofIL-4, IL-5, IL-6, IL-
10, and IL-13, decreased expression of
interferon-y and IL-2, and no effect on total
IgE and IgG.
Compared to other pollutants such as
ozone, DEP appears to be unique in its effect
on IgE production. The in vivo effect of
DEP on IgE isotype switch can be replicated
in vitro with extracts from DEP containing
the polyaromatic hydrocarbon (PAH) frac-
tion from these particles, as well as the spe-
cific PAH compounds phenanthrene and
2,3,7,8-tetracholorodibenzo-p-dioxin (56).
Thus, PAHs, by their action on B cells,
appear to play a central role in the effect of
diesel exhaust on allergic inflammation.
Additionally, DEPs can also promote CD80
(an important molecule for MHC class II
antigen presentation) expression in
macrophages as well as in enhanced LPS-
induced IL-10 responses. These effects on
macrophages could alter their ability to pre-
sent antigen in such a way as to promote
Th2 responses to those antigens.
ETS. There is extensive literature indicat-
ing that ETS is a significant exacerbating fac-
tor for a number ofrespiratory tract diseases,
including asthma, which has been extensively
reviewed (39-41). Asthma-specific end points
increased by ETS include the risk ofhospital-
ization, medication use, airway hyperrespon-
siveness and, rarely, atopy or increased IgE
(39-41). ETS or maternal smoking during
pregnancy appears to be an especially impor-
tant riskfactor for the development ofasthma
in the first year of life. However, despite
strong epidemiological evidence that ETS
poses a significant risk for asthma exacerba-
tion, candidate mechanisms ofaction remain
undefined (40).
Recently, tobacco smoke extracts were
shown to alter monocyte function in mice
(59). Among those functions suppressed are
those that are commonly mediated by inter-
feron-y, including phagocytosis ofopsonized
antigens, MHC class II molecule expression,
oxidative burst, and NO synthesis. Activities
not suppressed, including TNF-a production,
are not induced by interferon-y. Similarly,
PAHs, the same species of molecules that
likely mediate the Th2-promoting actions of
DEPs, are also found in ETS.
Endotoxin. An inability to respond to
LPS (mediated by CD14 receptor polymor-
phisms) may enhance initial expression ofa
Th2-immune phenotype (47). However, in
persons already sensitized, it seems likely that
LPS augments the expression ofTh2 inflam-
mation. There is evidence that levels ofLPS
in house dust are more predictive ofasthma
severity in mite-sensitive asthmatics than mite
allergen levels in the same samples (60).
Furthermore, asthmatics have increased non-
specific airway responsiveness after exposure
to LPS [reviewed by Peden (50)]. Atopic sub-
jects yield eosinophilic responses to LPS and
LPS pretreatment enhances response to
inhaled allergens (50,61). Likewise, allergen
challenge yields increased levels of CD14 in
bronchoalveolar lavage fluid and enhances
PMN and eosinophil responses to LPS in the
nasal airways (50,62). However, for the most
part, the ability ofLPS to induce asthma and
atopic responses has only been observed in
subjects already found to have atopy.
Ozone and other criteriapollutants. As
with LPS, ozone clearly has adverse effects on
persons already diagnosed as atopic or asth-
matic (48-51). This pollutant is linked to
increased medication use, increased hospital-
ization, and increased emergency room visits.
Likewise, in both animal and human models,
this gas can enhance both immediate and
late-phase inflammation associated with aller-
gen exposure and can directly induce
eosinophil responses in atopic subjects.
However, there is no clear indication that this
pollutant, SO2, or NO2 play a role in asthma
pathogenesis or the induction ofatopy. There
are several complete reviews outlining the
effects of ozone and other criteria air pol-
lutants in asthma and atopy (48-51).
Summary and Gaps in
Knowledge
The development of atopy is a complex
immune process. I have outlined some ofthe
processes involved in immune responsiveness,
including antigen presentation, action of
either CD8+ or CD4+ lymphocytes, and
expression of a Thl or Th2 phenotype for
CD4+-mediated responses. I also reviewed a
number ofdefects that exist in the immune
system that serve as experiments of nature,
which demonstrates the multitude ofpoten-
tial targets for environmental modification of
immune responsiveness.
These findings suggest that fetal immune
responsiveness mediated by CD4+ lympho-
cytes is skewed toward Th2 expression. In
turn, subsequent development ofatopic dis-
ease during postnatal life may actually be per-
sistence ofthe fetal atopic state. It has been
additionally suggested that the relative failure
of Th1 influences to deviate the immune
response away from a Th2 expression is
important in the development ofclinically
significant atopy. Some ofthis may be due to
certain genetic influences that support Th2
responses (genes supporting the production
ofIL-4) as well as genetic predisposition
against full development ofThl responses
(i.e., genes which might blunt production of
interferon-y). However flawed this hypothesis
may prove to be, it does provide a construct
on which we might begin to examine the role
ofenvironmental influences on the expression
ofatopic disease in postnatal life.
Superimposed on any genetic predisposi-
tion that may exist is the role ofenvironmen-
tal influences that might induce either Thl
responses (certain immunizations such as
BCG, bacterial infections and stimuli, and
colonization with bacteria) or Th2 responses
(early exposure to allergens, especially food
allergens and indoor aeroallergens). Other
influences may be important as well, includ-
ing toxicological stimuli that may shift the
immune response toward a Th2 response
(such as PAH moities from diesel exhaust and
tobacco smoke).
Another important question is ifthe tim-
ing of exposure to potential environmental
stresses is important in subsequent postnatal
expression ofan atopic/asthmatic phenotype
(Table 2). Other than carrying genes that
predispose an individual to developing
atopic responses, preconceptional exposure
of parents to environmental factors is
unlikely to be an important window of
exposure for the development of atopy in
subsequent offspring.
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Table 2. Probable importance of timing of exposure to environmental agents in development of postnatal asthma or
atopy.
Exposure period Maternal exposure Paternal exposure Environmental exposure of child
Preconception Very little to none Very little to none Not applicable
Prenatal Moderate Very little to none Not applicable
First 2years of life Small Very little Very important
After 2 years of age Small Very little Moderately important
With regard to prenatal exposures, it
seems reasonable to focus on maternal expo-
sures. This emphasis is justified by the obser-
vations that maternal smoking is more likely
to be associated with asthma and the fact that
there is at least some potential for transpla-
cental influences from the mother to her
fetus. However, there is little support that the
severity ofallergic disease in the mother influ-
ences expression ofatopy in her offspring. It
is reasonable to hypothesize that transplacen-
tal transfer ofTh2 cytokines, transplacental
exposure to allergens, or fetal exposure to
toxic immunomodulators (such as PAHs)
could influence the development ofatopy.
Thus, the effect ofenvironmental influences
during pregnancy are likely important.
However, it is likely that an even more
important window ofexposure for the impact
of environmental agents is during the first
year oflife. This could include allergen expo-
sure (food and airborne), natural or vaccine
stimulation ofThl responses, and the poten-
tial for agents such as PAH to modify ThI or
Th2 responses during this period. Several
studies indicate that the risk of developing
atopic disease and maintaining it throughout
life is greatest ifit occurs during the first year
oflife.
Many atopic infants lose a significant
degree ofatopic expression from 2 to 5 years
ofage and it is a well-recognized phenome-
non that children may grow out ofasthma by
puberty. It is interesting that one ofthe hall-
mark features ofThl immune maturation is
an ability to mount an adequate IgG response
to polysaccharide antigens, usually occurring
by 2 years of age. This suggests that avoid-
ance of pro-Th2 environmental stressors
(allergen avoidance and the avoidance of
environmental adjuvants ofTh2 responses
such as diesel exhaust and ETS) during the
toddler years is important. Also, it suggests
that potentially inappropriate removal ofThl
stimuli (such as gut flora), perhaps by the
inappropriate use ofantibiotics, might also
promote persistence ofatopy.
Although unique and very strong environ-
mental exposures might induce allergy during
adulthood, this is relatively rare. The best
examples of such adult-onset allergies are
occupational diseases, some ofwhich are "typ-
ical" Th2-based IgE responses to naturally
presented antigens, whereas others are unique
sensitizing agents that cause immunologically
unique disorders. Taken together, it seems
that the exposures to environmental stressors
during the perinatal, neonatal, and toddler
years are ofthe most importance. Likewise,
maternal rather than paternal influences dur-
ing perinatal life could be significant.
Environmental stresses that support Th2
inflammation are obviously important.
However, the impact ofstresses that decrease
Thl responses (including the production of
interferon-yand IL-12) cannot be ignored.
Finally, better understanding of the
molecular basis for the development ofatopy,
including production of relevant cytokines
and their receptors, antigen presentation,
T-cell influence on B-cell function and direct
alteration ofB-cell function, are essential to
appropriately identify immune processes that
may be targets for the action ofknown and as
yet unappreciated environmental agents
which influence the development of atopy
and asthma in susceptible people.
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